Skip to main content
Erschienen in: Drug Safety 11/2006

01.11.2006 | Original Research Article

Initiation of Acetylcholinesterase Inhibitors and Complications of Chronic Airways Disorders in Elderly Patients

verfasst von: Mr Evan L. Thacker, Sebastian Schneeweiss

Erschienen in: Drug Safety | Ausgabe 11/2006

Einloggen, um Zugang zu erhalten

Abstract

Background and objective: Acetylcholinesterase inhibitors (AChEIs), commonly prescribed in Alzheimer’s disease, may trigger complications of chronic airways disorders. The aim of this study was to determine whether initiation of therapy with AChEIs contributes to complications of chronic airways disorders in an elderly population.
Methods: Sequence-symmetry analysis was used to assess two cohorts of patients, both with a history of chronic airways disorders. Both cohorts comprised Medicare beneficiaries who received drug coverage through the Pennsylvania Pharmaceutical Assistance Contract for the Elderly, between 1997 and 2002. One cohort of 922 patients initiated treatment with an AChEI; the other cohort of 2819 patients initiated treatment with a β-adrenoceptor antagonist (β-blocker), a comparator drug also contraindicated in chronic airways disorders. The occurrence of the following four outcomes in claims data was assessed: (i) emergency room visits for complications of chronic airways disorders; (ii) hospitalisations for complications of chronic airways disorders; (iii) physician visits for complications of chronic airways disorders; and (iv) dispensing of an antibacterial and an oral corticosteroid on the same day. Rate ratios (RRs) were adjusted for age, sex, race, nursing home residence, cognitive status, severity of chronic airways disorders, comorbid illnesses and all other patient characteristics that can be assumed to remain constant over the study period.
Results: Initiators of AChEIs had no detectable increased rate of complications of chronic airways disorders. Adjusted RRs of the four outcomes ranged from 1.00 (95% CI 0.61, 1.62; p = 0.99) for physician visits to 1.64 (95% CI 0.55, 4.89; p = 0.37) for emergency room visits, none reaching statistical significance. In contrast, β-blocker initiators had significantly increased rates of all four outcomes after treatment, with adjusted RRs ranging from 1.97 (95% CI 1.18, 3.29; p = 0.009) for emergency room visits to 2.76 (95% CI 1.71, 4.45; p < 0.0001) for dispensing of an antibacterial and oral corticosteroid on the same day.
Conclusion: These results suggest that, in current clinical practice, physicians can prescribe AChEIs safely to elderly patients with chronic airways disorders, while β-blocker prescribing continues to result in adverse health outcomes.
Literatur
1.
Zurück zum Zitat McCormick WC, Kukull WA, van Belle G, et al. Symptom patterns and comorbidity in the early stages of Alzheimer’s disease. J Am Geriatr Soc 1994 May; 42(5): 517–21CrossRefPubMed McCormick WC, Kukull WA, van Belle G, et al. Symptom patterns and comorbidity in the early stages of Alzheimer’s disease. J Am Geriatr Soc 1994 May; 42(5): 517–21CrossRefPubMed
2.
Zurück zum Zitat National Center for Health Statistics. National Nursing Home Survey public-use data files 1999 [online]. Available from URL: http://www.cdc.gov/nchs/about/major/nnhsd/nnhsd.htm [Accessed 2005 Apr 30] National Center for Health Statistics. National Nursing Home Survey public-use data files 1999 [online]. Available from URL: http://​www.​cdc.​gov/​nchs/​about/​major/​nnhsd/​nnhsd.​htm [Accessed 2005 Apr 30]
3.
Zurück zum Zitat Doraiswamy PM, Leon J, Cummings JL, et al. Prevalence and impact of medical comorbidity in Alzheimer’s disease. J Gerontol A Biol Sci Med Sci 2002 Mar; 57(3): M173–7CrossRefPubMed Doraiswamy PM, Leon J, Cummings JL, et al. Prevalence and impact of medical comorbidity in Alzheimer’s disease. J Gerontol A Biol Sci Med Sci 2002 Mar; 57(3): M173–7CrossRefPubMed
4.
Zurück zum Zitat Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003 Aug; 60(8): 1119–22CrossRefPubMed Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003 Aug; 60(8): 1119–22CrossRefPubMed
5.
Zurück zum Zitat Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance: United States, 1971-2000. MMWR Surveill Summ 2002 Aug; 51(6): 1–16 Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance: United States, 1971-2000. MMWR Surveill Summ 2002 Aug; 51(6): 1–16
6.
Zurück zum Zitat Mannino DM, Homa DM, Akinbami LJ, et al. Surveillance for asthma: United States, 1980-1999. MMWR Surveill Summ 2002 Mar; 51(1): 1–13 Mannino DM, Homa DM, Akinbami LJ, et al. Surveillance for asthma: United States, 1980-1999. MMWR Surveill Summ 2002 Mar; 51(1): 1–13
7.
Zurück zum Zitat Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000 May; 117(5 Suppl. 2): 380S–5SCrossRefPubMed Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000 May; 117(5 Suppl. 2): 380S–5SCrossRefPubMed
8.
Zurück zum Zitat Kreit JW, Rogers RM. Chronic obstructive pulmonary disease and emphysema. In: Davis GS, editor. Medical management of pulmonary diseases. New York (NY): Marcel Dekker Inc, 1999: 451–74 Kreit JW, Rogers RM. Chronic obstructive pulmonary disease and emphysema. In: Davis GS, editor. Medical management of pulmonary diseases. New York (NY): Marcel Dekker Inc, 1999: 451–74
9.
Zurück zum Zitat Palm KH, Decker WW. Acute exacerbations of chronic obstructive pulmonary disease. Emerg Med Clin North Am 2003 May; 21(2): 331–52CrossRefPubMed Palm KH, Decker WW. Acute exacerbations of chronic obstructive pulmonary disease. Emerg Med Clin North Am 2003 May; 21(2): 331–52CrossRefPubMed
10.
Zurück zum Zitat Lee-Chiong Jr TL, Matthay RA. COPD and the left heart. In: Similowski TS, Whitelaw WA, Derenne J-P, editors. Clinical management of chronic obstructive pulmonary disease. New York (NY): Marcel Dekker Inc, 2002: 533–48 Lee-Chiong Jr TL, Matthay RA. COPD and the left heart. In: Similowski TS, Whitelaw WA, Derenne J-P, editors. Clinical management of chronic obstructive pulmonary disease. New York (NY): Marcel Dekker Inc, 2002: 533–48
11.
Zurück zum Zitat Sweetman SC, editor. Martindale: the complete drug reference. 34th ed. London: Pharmaceutical Press, 2005 Sweetman SC, editor. Martindale: the complete drug reference. 34th ed. London: Pharmaceutical Press, 2005
12.
Zurück zum Zitat Barnes PJ. Autonomic pharmacology of the airways. In: Chung KF, Barnes PJ, editors. Pharmacology of the respiratory tract: experimental and clinical research. New York (NY): Marcel Dekker Inc, 1993: 415–456 Barnes PJ. Autonomic pharmacology of the airways. In: Chung KF, Barnes PJ, editors. Pharmacology of the respiratory tract: experimental and clinical research. New York (NY): Marcel Dekker Inc, 1993: 415–456
13.
Zurück zum Zitat Eisai Co Ltd. Aricept prescribing information 2002 [online]. Available from URL: http://www.aricept.com/pi/aricept_pi.htm [Accessed 2004 May 12] Eisai Co Ltd. Aricept prescribing information 2002 [online]. Available from URL: http://​www.​aricept.​com/​pi/​aricept_​pi.​htm [Accessed 2004 May 12]
14.
Zurück zum Zitat Novartis Pharmaceuticals Corporation. Exelon prescribing information 2001 [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/exelon.pdf [Accessed 2004 May 17] Novartis Pharmaceuticals Corporation. Exelon prescribing information 2001 [online]. Available from URL: http://​www.​pharma.​us.​novartis.​com/​product/​pi/​pdf/​exelon.​pdf [Accessed 2004 May 17]
15.
Zurück zum Zitat Ortho-McNeil Neurologics, Inc. Razadyne Prescribing Information 2005 [online]. Available from URL: http://www.razadyne.com/active/janus/en_US/assets/common/company/pi/razadyne.pdf [Accessed 2005 Nov 8] Ortho-McNeil Neurologics, Inc. Razadyne Prescribing Information 2005 [online]. Available from URL: http://​www.​razadyne.​com/​active/​janus/​en_​US/​assets/​common/​company/​pi/​razadyne.​pdf [Accessed 2005 Nov 8]
16.
Zurück zum Zitat Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998 May; 158(9): 1021–31CrossRefPubMed Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998 May; 158(9): 1021–31CrossRefPubMed
17.
Zurück zum Zitat Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology 1998 Jan; 50(1): 136–45CrossRefPubMed Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology 1998 Jan; 50(1): 136–45CrossRefPubMed
18.
Zurück zum Zitat Relkin NR, Reichman WE, Orazem J, et al. A large, community-based, open-label trial of donepezil in the treatment of Alzheimer’s disease. Dement Geriatr Cogn Disord 2003; 16(1): 18–24CrossRef Relkin NR, Reichman WE, Orazem J, et al. A large, community-based, open-label trial of donepezil in the treatment of Alzheimer’s disease. Dement Geriatr Cogn Disord 2003; 16(1): 18–24CrossRef
19.
Zurück zum Zitat Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999 Mar; 318(7184): 633–8CrossRefPubMedPubMedCentral Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999 Mar; 318(7184): 633–8CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998; 1: 55–65 Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998; 1: 55–65
21.
Zurück zum Zitat Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000 Jun; 54(12): 2261–8CrossRefPubMed Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000 Jun; 54(12): 2261–8CrossRefPubMed
22.
Zurück zum Zitat Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000 Jun; 54(12): 2269–76CrossRefPubMed Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000 Jun; 54(12): 2269–76CrossRefPubMed
23.
Zurück zum Zitat Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000 Dec; 321(7274): 1445–9CrossRefPubMedPubMedCentral Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000 Dec; 321(7274): 1445–9CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Lyketsos CG, Reichman WE, Kershaw P, et al. Long-term outcomes of galantamine treatment in patients with Alzheimer disease. Am J Geriatr Psychiatry 2004 Sep–Oct; 12(5): 473–82CrossRefPubMed Lyketsos CG, Reichman WE, Kershaw P, et al. Long-term outcomes of galantamine treatment in patients with Alzheimer disease. Am J Geriatr Psychiatry 2004 Sep–Oct; 12(5): 473–82CrossRefPubMed
25.
Zurück zum Zitat Frolich L, Klinger T, Berger FM. Treatment with donepezil in Alzheimer patients with and without cerebrovascular disease. J Neurol Sci 2002 Nov; 203–204: 137–9 Frolich L, Klinger T, Berger FM. Treatment with donepezil in Alzheimer patients with and without cerebrovascular disease. J Neurol Sci 2002 Nov; 203–204: 137–9
26.
Zurück zum Zitat Schmidt R, Lechner A, Petrovic K. Rivastigmine in outpatient services: experience of 114 neurologists in Austria. Int Clin Psychopharmacol 2002 Mar; 17(2): 81–5CrossRefPubMed Schmidt R, Lechner A, Petrovic K. Rivastigmine in outpatient services: experience of 114 neurologists in Austria. Int Clin Psychopharmacol 2002 Mar; 17(2): 81–5CrossRefPubMed
27.
Zurück zum Zitat Aguglia E, Onor ML, Saina M, et al. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Curr Med Res Opin 2004 Nov; 20(11): 1747–52CrossRefPubMed Aguglia E, Onor ML, Saina M, et al. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Curr Med Res Opin 2004 Nov; 20(11): 1747–52CrossRefPubMed
28.
Zurück zum Zitat Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000 May; 117(5 Suppl. 2): 398S–401SCrossRefPubMed Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000 May; 117(5 Suppl. 2): 398S–401SCrossRefPubMed
29.
Zurück zum Zitat Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 2003; 21Suppl. 41: 46S–53SCrossRef Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 2003; 21Suppl. 41: 46S–53SCrossRef
30.
Zurück zum Zitat Petri H, de Vet HC, Naus J, et al. Prescription sequence analysis: a new and fast method for assessing certain adverse reactions of prescription drugs in large populations. Stat Med 1988 Nov; 7(11): 1171–5CrossRefPubMed Petri H, de Vet HC, Naus J, et al. Prescription sequence analysis: a new and fast method for assessing certain adverse reactions of prescription drugs in large populations. Stat Med 1988 Nov; 7(11): 1171–5CrossRefPubMed
31.
Zurück zum Zitat Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology 1996 Sep; 7(5): 478–84CrossRefPubMed Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology 1996 Sep; 7(5): 478–84CrossRefPubMed
32.
Zurück zum Zitat Petri H, Leufkens H, Naus J, et al. Rapid method for estimating the risk of acutely controversial side effects of prescription drugs. J Clin Epidemiol 1990; 43(5): 433–9CrossRefPubMed Petri H, Leufkens H, Naus J, et al. Rapid method for estimating the risk of acutely controversial side effects of prescription drugs. J Clin Epidemiol 1990; 43(5): 433–9CrossRefPubMed
33.
Zurück zum Zitat van Dijk KN, de Vries CS, van den Berg PB, et al. Constipation as an adverse effect of drug use in nursing home patients: an overestimated risk. Br J Clin Pharmacol 1998 Sep; 46(3): 255–61CrossRefPubMedPubMedCentral van Dijk KN, de Vries CS, van den Berg PB, et al. Constipation as an adverse effect of drug use in nursing home patients: an overestimated risk. Br J Clin Pharmacol 1998 Sep; 46(3): 255–61CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Bytzer P, Hallas J. Drug-induced symptoms of functional dyspepsia and nausea: a symmetry analysis of one million prescriptions. Aliment Pharmacol Ther 2000 Nov; 14(11): 1479–84CrossRefPubMed Bytzer P, Hallas J. Drug-induced symptoms of functional dyspepsia and nausea: a symmetry analysis of one million prescriptions. Aliment Pharmacol Ther 2000 Nov; 14(11): 1479–84CrossRefPubMed
35.
Zurück zum Zitat Movig KL, Leufkens HG, Belitser SV, et al. Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiol Drug Saf 2002 Jun; 11(4): 271–9CrossRefPubMed Movig KL, Leufkens HG, Belitser SV, et al. Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiol Drug Saf 2002 Jun; 11(4): 271–9CrossRefPubMed
36.
Zurück zum Zitat Hersom K, Neary MP, Levaux HP, et al. Isotretinoin and antidepressant pharmacotherapy: a prescription sequence symmetry analysis. J Am Acad Dermatol 2003 Sep; 49(3): 424–32CrossRefPubMed Hersom K, Neary MP, Levaux HP, et al. Isotretinoin and antidepressant pharmacotherapy: a prescription sequence symmetry analysis. J Am Acad Dermatol 2003 Sep; 49(3): 424–32CrossRefPubMed
37.
Zurück zum Zitat Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York (NY): John Wiley & Sons Inc, 2000CrossRef Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York (NY): John Wiley & Sons Inc, 2000CrossRef
38.
Zurück zum Zitat The Joint National Committee. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997 Nov; 157 (21): 2413–46CrossRef The Joint National Committee. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997 Nov; 157 (21): 2413–46CrossRef
39.
Zurück zum Zitat Craig T, Richerson HB, Moeckli J. Problem drugs for patients with asthma. Compr Ther 1996 Jun; 22(6): 339–44PubMed Craig T, Richerson HB, Moeckli J. Problem drugs for patients with asthma. Compr Ther 1996 Jun; 22(6): 339–44PubMed
40.
Zurück zum Zitat O’Malley K, Cox JP, O’Brien E. Choice of drug treatment for elderly hypertensive patients. Am J Med 1991 Mar; 90Suppl. 3A: 27S–33SCrossRefPubMed O’Malley K, Cox JP, O’Brien E. Choice of drug treatment for elderly hypertensive patients. Am J Med 1991 Mar; 90Suppl. 3A: 27S–33SCrossRefPubMed
41.
Zurück zum Zitat White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease 6: the aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 2003 Jan; 58(1): 73–80CrossRefPubMedPubMedCentral White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease 6: the aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 2003 Jan; 58(1): 73–80CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health 2000; 21: 193–221CrossRefPubMed Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health 2000; 21: 193–221CrossRefPubMed
Metadaten
Titel
Initiation of Acetylcholinesterase Inhibitors and Complications of Chronic Airways Disorders in Elderly Patients
verfasst von
Mr Evan L. Thacker
Sebastian Schneeweiss
Publikationsdatum
01.11.2006
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 11/2006
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200629110-00007

Weitere Artikel der Ausgabe 11/2006

Drug Safety 11/2006 Zur Ausgabe

Review Article

Betahistine